What is the recommended diagnostic workup for suspected anaplastic large cell lymphoma?

Diagnostic Workup for Anaplastic Large Cell Lymphoma

For suspected systemic ALCL, obtain a tissue biopsy with comprehensive morphologic evaluation, immunohistochemistry (including CD30, ALK, and pan-T-cell markers), flow cytometry, conventional cytogenetics, and molecular studies including T-cell receptor gene rearrangement analysis. 1

Initial Clinical Assessment

Document the following specific clinical features:

• Presence and location of lymphadenopathy or extranodal masses (mediastinal, hepatosplenic, cutaneous, or soft tissue involvement) 1
• Constitutional symptoms including fever, night sweats, and weight loss 2
• Time course of symptom development and any history of prior lymphoproliferative disorders 3
• For patients with breast implants: onset of breast swelling, asymmetry, or peri-implant fluid collection, typically occurring >1 year (median 8-10 years) after implantation 4

Tissue Acquisition Strategy

For Systemic Disease

Obtain an excisional or incisional tissue biopsy rather than fine needle aspiration, as ALCL can show focal involvement and requires adequate tissue for comprehensive analysis 4. Core needle biopsy may be acceptable if excisional biopsy is not feasible, but ensure sufficient material for all ancillary studies 5.

For Breast Implant-Associated ALCL

When peri-implant effusion is present, perform ultrasound-guided aspiration as the primary diagnostic procedure 4. Process the fresh, unfixed effusion fluid immediately with:

• Cytocentrifugation to produce air-dried smears stained with Wright-Giemsa or Romanowsky-type stains 4
• Cell block preparation for H&E staining, immunohistochemistry, and PCR-based T-cell receptor gene rearrangement studies 4
• Flow cytometry if laboratory has validated CD30 antibody, though this is second-line to cytology and cell block 4

Essential Pathologic Studies

Morphologic Evaluation

Examine tissue for:

• Large pleomorphic cells with irregular nuclei, prominent nucleoli, and abundant basophilic cytoplasm 4
• "Hallmark cells" with horseshoe- or kidney-shaped nuclei (characteristic but not always present) 4
• Growth patterns: common, lymphohistiocytic, small cell, Hodgkin-like, or sarcomatoid variants 6, 7

Immunohistochemistry Panel

Mandatory markers:

• CD30: Must show strong, uniform expression 4, 1
• ALK (ALK-1): Distinguishes ALK-positive from ALK-negative ALCL; critical for prognosis 1, 2
• Pan-T-cell markers: CD3, CD2, CD5, CD7 (often show aberrant/incomplete expression) 1
• CD4 and CD8 1

Additional markers to exclude mimics:

• CD20, PAX5, CD138: To exclude B-cell lymphomas 4
• Pan-cytokeratin: To exclude poorly differentiated carcinoma 4
• CD15: May be positive in ALCL but helps distinguish from classical Hodgkin lymphoma 7
• EBV-EBER in situ hybridization: To exclude EBV-associated lymphomas 4
• Cytotoxic markers (TIA-1, granzyme B, perforin): Often positive in ALCL 1

Flow Cytometry

If performed, assess for:

• CD45+, CD30+, CD3- or dim pattern typical of ALCL 4
• Aberrant T-cell antigen expression 1

Pitfall: CD30 can be expressed by activated reactive T cells; correlation with morphology and light scatter properties is essential 4.

Molecular and Cytogenetic Studies

Required studies:

• T-cell receptor (TCR) gene rearrangement by PCR (preferably BIOMED-2 primers): Clonal rearrangements support neoplastic T-cell process 4
• Conventional cytogenetics (karyotype) on fresh tissue 1

For ALK-negative ALCL, consider:

• FISH for DUSP22 rearrangement: Associated with favorable prognosis similar to ALK-positive disease 1, 3
• FISH for TP63 rearrangement if IHC shows TP63 positivity 1, 3
• FISH for JAK2 rearrangement in selected cases 3

Staging Workup

Once diagnosis is confirmed:

• PET/CT scan or CT chest/abdomen/pelvis with contrast 1
• Bone marrow biopsy and aspirate with morphology, flow cytometry, and cytogenetics 1
• Complete blood count with differential 1
• Comprehensive metabolic panel, LDH, uric acid, phosphate (assess tumor burden and lysis risk) 8
• HIV and HTLV-1 serology in selected cases (HTLV-1 positivity changes diagnosis to adult T-cell leukemia/lymphoma) 1
• Echocardiogram or MUGA scan if anthracycline-based therapy planned 1

For BIA-ALCL Staging

At capsulectomy, perform systematic mapping of the fibrous capsule to assess for microscopic tumor involvement and depth of capsular invasion (stages T1-T4) 4. Assess lymph nodes by excisional biopsy rather than FNA due to propensity for focal involvement 4.

Critical Diagnostic Pitfalls

• Small cell variant ALCL may be misdiagnosed as peripheral T-cell lymphoma NOS; always assess CD30 and ALK in suspected T-cell neoplasms even when large cells are not prominent 9
• Cytokeratin expression can occur in ALCL and lead to misdiagnosis as carcinoma 7
• Sinusoidal growth pattern may mimic metastatic carcinoma or myeloid sarcoma 7
• In patients with prior mycosis fungoides, distinguish CD30+ transformation from de novo ALCL by clinical history and comparison with prior biopsies 3
• BIA-ALCL diagnosis can be missed if effusion fluid is not properly processed or if capsulectomy specimen is inadequately sampled 4